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Background: Recently several reports have indicated that elevated expression of DKK1 is tightly associated with the
progression of hepatocellular carcinoma (HCC). However, the biological function of DKK1 in HCC has not yet been
well documented.
Methods: In this study, the role of DKK1 in tumor cell proliferation, migration and invasion was investigated using
MTT, colony formation, wound scratch, transwell assays, and also human HCC samples.
Results: Both gain- and loss-of-function studies showed that DKK1 did not influence the tumor cell proliferation
and colony formation, while dramatically promoted HCC cell migration and invasion. Subsequent investigations
revealed that β-catenin was an important target of DKK1. The blocking of β-catenin by pharmacological inhibitor
antagonized the function of DKK1, whereas introduction of β-catenin by transfection with plasmids or treatment
with GSK3β inhibitor phenocopied the pro-migration and pro-invasion effects of DKK1. We further disclosed that
DKK1 exerted its pro-invasion function, at least in part, by promoting β-catenin expression, in turn, upregulating the
expression of matrix metalloproteinase 7 (MMP7), which was independent of the canonical Wnt signaling pathway.
Moreover, introduction of MMP7 significantly enhanced the ability of HCC cells to invade extracellular matrix gel
in vitro. Consistently, in human HCC tissues, DKK1 level was positively correlated with β-catenin expression, as well
as tumor metastasis.
Conclusion: Taken together, these results demonstrated that DKK1 is overexpressed in HCC; moreover, ectopic
expression DKK1 promotes HCC cell migration and invasion at least partly through β-catenin/MMP7 signaling axis,
suggesting that DKK1 may be a promising target for HCC therapy.
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Hepatocellular carcinoma (HCC) is one of the most com-
monly diagnosed cancers, ranking as the third leading
cause of all cancer-related death in the world [1]. Despite
some advances in early detection and the use of modern
surgical techniques in combination with various treatment
modalities, such as radiotherapy and chemotherapy, to
date, the prognosis of the patients with HCC still remains
poor. It has been shown that only 30%-40% of patients are* Correspondence: wcjsxq@henu.edu.cn; xiesq@henu.edu.cn
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reproduction in any medium, provided the oramenable to potentially curative therapies, because most
patients are often at advanced stage of disease at the time
of diagnosis [2]. Moreover, the overall 5-year survival rate
of HCC patients remains unsatisfactory, mainly because of
a high incidence of recurrence and metastasis after hepatic
resection [3]. It is well-believed that elucidation of the
underlying molecular basis involved in HCC progression
and metastasis is very important for the development of
effective HCC therapeutic agents. In order to improve
HCC treatments and outcomes, therefore, identifying the
potential molecules that promote HCC progression and
metastasis are urgently needed.
Dickkopf1 (DKK1), a secreted protein involved in head
formation in embryonic development, binds to the low-td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Wnt co-receptor and prevents the formation of active
Wnt-Frizzled-LRP5/6 receptor complexes, thus blocking
the canonical Wnt/β-catenin signaling pathway [4]. Nu-
merous studies have shown that DKK1 was implicated
in the control of various pathological and physiological
processes, including adult hippocampal neurogenesis [5],
osteoclastogenesis [6], tumor cell proliferation, survival,
migration and invasion [7,8]. However, the role of DKK1
in tumor biology is controversial. Several studies have
shown that DKK1 can either inhibit or promote tumor
progression and metastasis. On one hand, DKK1 has been
shown to inhibited tumorigenesis. For example, González-
Sancho et al. found that DKK1 expression decreases in
human colon tumors, suggesting that DKK1 may act as a
tumor suppressor gene in this neoplasia [9]. Indeed, up-
regulation of DKK1 causes a decrease in colon cancer cell
proliferation, clonogenicity, migration, and invasiveness
[10,11]. On the other hand, overexpression of DKK1 was
found in 126 out of 180 human non-small cell lung can-
cers, 59 of 85 small cell lung cancers, and 51 of 81 eso-
phageal squamous cell carcinomas patients [12]. High
expression of DKK1 has also been reported in breast and
kidney cancers [13]. A recent research article showed that
high expression of DKK1 is related to lymphatic metas-
tasis and indicates poor prognosis in intrahepatic cho-
langiocarcinoma (ICC) patients after surgery, vice versa,
depletion of DKK1 using small interfering RNA results in
a decrease in ICC cell migration and invasion [8]. Taken
together, all these findings suggest that DKK1 performs an
oncogenic or a tumor-suppressing function depends on
the cell type or context.
Several years ago, Qin et al. reported that overexpression
of DKK1 by transfection is able to inhibit the growth and
migration. But vice versa, reduction of DKK1 expression
by RNA interference is able to increase the migration in a
model of hepatocellular carcinoma cells [14]. However, re-
cently several research studies indicated that elevated ex-
pression of DKK1 was found in both tissue and serum
samples from patients with HCC [15-17]. Moreover, over-
expression of DKK1 not only enhances the tumor forma-
tion efficiency and tumor growth but also promotes the
cell invasion and metastasis in vitro and in vivo, whereas
knockdown of DKK1 significantly reduced both migratory
and invasive abilities of HCC cells [15,17]. Therefore,
whether DKK1 is an oncogene or a tumor suppressor in
HCC remains to be further investigated. Furthermore, the
precise mechanism of DKK1 involved in tumorigenesis
has not been well-documented.
In this present study, both gain- and loss-of-function
studies showed that DKK1 did not influence HCC cell
proliferation and colony formation, while dramatically
promoted HCC cell migration and invasion. We further
confirmed that DKK1 exerted its pro-invasion function,at least in part, by promoting β-catenin expression, in turn,
upregulating the expression of matrix metalloproteinase 7
(MMP7), which was independent of the canonical Wnt sig-
naling pathway. Moreover, introduction of MMP7 signifi-
cantly enhanced the ability of HCC cells to invade
extracellular matrix gel in vitro. Our findings highlight the
oncogenic role of DKK1 in promoting HCC cell migration
and invasion through activation of β-catenin/MMP7 sig-
naling pathway, implicating that DKK1 may serve as a po-
tential target for HCC therapy.
Materials and methods
Materials
3-(4, 5-dimethylthiazol)-2, 5-diphenyltetrazolium brom-
ide (MTT), Hoechst33342, G418 and LiCl were pur-
chased from Sigma (St. Louis, MO, USA). RPMI 1640
and fetal calf serum (FCS) were purchased from Gibco
(Grand Island, NY, USA). The sources of primary anti-
bodies used for Western blot: DKK1 (cat. sc-25516),
LRP6 (cat. sc-17982), GSK3β (cat. sc-53931), β-catenin
(cat. sc-7199) and MMP7 (cat. sc-101566) as well as the
corresponding horseradish peroxidase-conjugated sec-
ond antibodies were all purchased from Santa Cruz Bio-
technologies (Santa Cruz, CA, USA). Cy3-labeled goat
anti-mouse second antibody was purchased from Beyo-
time Institute of Biotechnology (cat. A0521, Shanghai,
China). All other chemicals used in this study were com-
mercial products of reagent grade.
Human tissue specimens and cell lines
Human HCC (30 cases of primary, 41 cases of metasta-
sis) and adjacent non-tumor liver tissues were collected
from 71 patients undergoing resection of HCC at the
Huai-He Hospital, Henan University (Kaifeng, China).
All tissues were classified according to the tumor-node-
metastasis classification system of the union for Inter-
national Cancer Control. Informed consent was obtained
from each patient, and the study was approved by the
Institute Research Ethics Committee at the hospital.
Cell lines, derivative from human HCC (HepG2,
SMMC7721, Huh7 and Bel7402) and normal liver cell line
(QSG-7701) were used in this study. All of them were pur-
chased from the cell bank of the Chinese Academy of Sci-
ence (Shanghai, China), these cells were maintained in
RPMI1640 medium containing 10% fetal calf serum, 100
units/mL penicillin, and 100 μg/mL streptomycin, at 37°C
in a humidified incubator containing 5% CO2.
Plasmid construction
The full-length coding region (801 bp) of DKK1 was amp-
lified from human genomic DNA by reverse transcription-
polymerase chain reaction (RT-PCR) using the following
primers: DKK1-sense 5′-CCG CTC GAG ATG ATG
GCT CTG GGC GCA GCGGG-3′, and antisense 5′-
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CAAGT-3′, then the PCR products were digested with
XhoI/BamHI and were inserted into the pIRES2-EGFP
vector (Clontech).The recombinant construct was verified
by direct DNA sequencing.
For the construction of siRNA expression plasmids, A
siRNA sequence targeted human DKK1 transcript (ac-
cession no. NM_012242.2; sense 5′-GGAATAAGTACC
AGACCATTG-3′) was selected for RNA interference
(RNAi). This sequence showed no homology with other
known human genes. A scrambled sequence (sense 5′-
GGAATAAGACCATGACCATTG-3′), which is no homo-
logous to any human DNA sequence, served as a negative
control. Two complementary oligonucleotides that con-
tain both sense and antisense siRNA sequences, the loop
sequence (5′-TTCAAGAGA-3′) and the flanking BamH I
and EcoR I sites were synthesized chemically. Then these
two complementary oligonucleotides were annealed and
ligated into the linearized pSIREN-Shuttle (Clontech).
Each recombinant construct was sequenced to confirm
the right sequence of insert. The construct contained
siDKK1 sequence was designated as pSIREN-Shuttle-
siDKK1, while the plasmid with scrambled sequence was
named as pSIREN-Shuttle-Control.
Transfection
For transfection, HepG2 and Bel7402 cells were seeded in
24-well plates at 5 × 104 per well and incubated at 37°C in
a humidified incubator containing 5% CO2. The next day,
when these cells were about 80% confluence, cells were
transfected with TurboFect™ in vitro Transfection Reagent
according to the manufacturer’s instructions. These
transfected cells were selected with 0.1 mg/mL G418
for at least 2 weeks, and then the stable plasmid-
transfected clones were generated by using limiting dilu-
tion analysis in 96-well plates. The clones derived from
HepG2 cells stably transfected with pIRES2-EGFP-DKK1
or pIRES2-EGFP vector were classified as DKK1 and
Vector respectively; whereas the clones derived from
Bel7402 cells stably transfected with pSIREN-Shuttle-siDKK1
or pSIREN-Shuttle-Control were classified as shDKK1 and
shControl respectively. For β-catenin and MMP7 transfec-
tions, tumor cells transiently transfected with human beta-
catenin pcDNA3 (plasmid 16828; Addgene, Cambridge,
MA), pcDNA3 (Invitrogen), pCMV6-XL5-MMP7 and pCM
V6-XL5 (OriGene, USA) using TurboFect™ in vitro Trans-
fection Reagent for 36 h, then were applied to other
expriements.
Cell growth curve analysis
The MTT assay was used to detect the proliferation rate
of tumor cells. Briefly, 2000 cells per well were plated
in 96-well plates and incubated 1, 2, 3, 4, 5, 6 and 7d,
respectively. At indicated time point, the process wasperformed as described before [18]. Briefly, 50 μl of
MTT reagent (1 mg/mL) was added and incubated for
4 h at 37°C in a humidified incubator containing 5%
CO2. Supernatants were removed from the wells, and
then 100 μl DMSO was added to solubilize the crystal
products at room temperature for 10 min. The absorbance
(OD) was measured with a microplate reader (Bio-Rad) at
a wavelength of 570 nm.
RNA isolation and RT-PCR
For PCR, total RNA was extracted from sub-confluent
using TRIzol reagent (Invitrogen). Two microgram of
total RNA was subjected to DNase I digestion (1 U/μL,
Fermentas, Hanover, MD) at 37°C for 30 min, and then
the DNase I was heated inactivation at 70°C for 15 min,
followed by reverse-transcription using PrimeScript™ Re-
verse Transcriptase (Takara). Semiquantitative RT-PCR
was performed using primers listed in Additional file 1:
Table S1. All PCR reactions were done using the follow-
ing conditions: 95°C 5 min, 95°C 45 s, annealing at
different temperatures for each gene respectively 45 s,
extension 72°C 1 min for 30 cycles, and a final extension
at 72°C for 10 min. All PCR products were separated by
electrophoresis on 1.0% agarose gels.
Colony formation assay
The colony formation assay was performed as previously
described with some modification [19]. Briefly, a total of
400 cells every well were seeded into a fresh 6-well plate
and incubated in RPMI1640 containing 10% FCS, cell
medium was changed every 3 d for 15 d until visible col-
onies formed. Colonies were fixed with methanol and
stained with 0.1% crystal violet in 20% methanol for
20 min. Microscopic colonies composed of more than
50 cells were counted in each well.
TCF luciferase reporter assay
HCC cells grown in 24-well plates were transiently
transfected with M50 Super 8x TOPFlash with the wild-
type TCF binding sites or its control M51 Super 8X
FOPflash with the mutant TCF binding sites ((plasmid
12456 or plasmid 12457, Addgene, Cambridge, MA), in
combination with pRL-TK (Renilla luciferase; Promega,
Madison, WI) using TurboFect™ in vitro Transfection
Reagent (Fermentas) according to the manufacturer’s in-
structions. After 36 h, the transfected cells were lysed
and luciferase activity measurement was performed with
the Dual-Luciferase Reporter Assay System (Promega).
Wound scratch assay
The wound scratch assay was performed as described
previously [15]. Briefly, cells were plated in a 24-well
plate and grown to a confluence cell monolayer over-
night prior to serum starvation for 24 h. After scratching
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ing cells, culture medium was removed and wells were
washed three times with PBS. The width of the wound
was measured and recorded as t = 0. The cells were then
allowed to migrated back into the wounded area, 24 h
latter, the width of the open area was measured. Cell mi-
gration was expressed as the percentage of the gap (t =
24 h) relative to the primary width of the open area (t =
0 h). All experiments were performed in triplicate.
Cell migration and invasion assay
The migration and invasion assays were performed as in a
24-well Boyden chamber with 8 μm pore size polycarbon-
ate membrane (Corning, NY, USA), as previously de-
scribed [20]. For migration assay, 200 μL of serum-free
medium (containing 1 × 105 cells) was added to the upper
compartment of the chamber, while the lower compart-
ment was filled with 600 μL of RPMI 1640 supplemented
with 10% FBS. After incubation at 37°C for 24 h, the
tumor cells remaining inside the upper chamber were re-
moved with cotton swabs. The cells on the lower surface
of the membrane were stained with 0.1% crystal violet
after fixation with methanol, and then counted under a
light microscope. The invasion assay was done by the
same procedure, except that the membrane was coated
with Matrigel to form a matrix barrier, and 3 × 104 tumor
cells were added to the upper chamber.
Immunofluorescence microscopy
The immunofluorescence staining was carried out as pre-
viously described with some changes [20]. Briefly, tumor
cells were washed three times with ice-cold PBS, fixed in
4.0% paraformaldehyde. After permeabilization with 0.1%
Triton X-100, cells were blocked of nonspecific binding by
incubation with 5% normal goat serum in PBS. Afterwards,
cells were incubated with the rabbit polyclonal β-catenin
antibody overnight at 4°C. The staining was completed
with Cy3-labeled goat anti-rabbit second antibody (1:500,
Beyotime, China) incubation for 1 h at room temperature,
and nuclei was counterstained with Hoechst33342 (10 μg/
mL, Sigma, USA) for 30 min at dark. All photographs were
taken by using High content screening (HCS) (Thermo
Scientific Cellomics ArrayScan Vti, Cellomics, Inc., Pitts-
burgh, PA).
Western blot analysis
Western blot analysis was performed as our described
previously [18]. Briefly, cell pellets were washed thrice
with ice-cold phosphate buffered saline (PBS) and were
lysed with RIPA buffer (Beyotime, China). The total pro-
tein concentration was determined using a BCA assay
kit (Beyotime, China). Samples were denatured in 5 ×
SDS-sample buffer at 95°C for 5 min. Equal amounts of
total proteins were separated using 12% SDS-PAGE, andthen transferred onto PVDF membranes. Membranes
were then blocked by 5% dried skimmed milk in PBST
at room temperature for 1 h. After blocking, membranes
were incubated with corresponding primary antibodies
overnight at 4 °C. After washed three times with PBST,
the membranes were incubated with appropriate HRP-
conjugated secondary antibody, and then washed three
times with PBST. Proteins were detected by using the
ECL plus reagents (Beyotime, China).
Immunohistochemical (IHC) staining
Formalin-fixed and Paraffin-embedded tissue sections
were de-paraffinized in xylene, rehydrated through graded
ethanol, quenched for endogenous peroxidase activity in
0.3% hydrogen peroxide, and processed for antigen re-
trieval in citrate buffer (pH 6.0) for 10 min by microwave
heating. Following overnight incubation at 4°C using
rabbit mAb against human DKK1 (1:200) or β-catenin
(1:100). Immunostaining was performed with an optimal
amount of HRP-conjugated secondary antibody for 1 h at
room temperature and DAB was used as chromogen. Sub-
sequently, sections were counterstained with hematoxylin.
DKK1 and β-catenin expression were evaluated under
a light microscope at a magnification of 200×. For each
specimen, five images of representative areas were ac-
quired and tumor cells were counted. For human sam-
ples, IHC scoring was performed using a modified
Histo-score (H-score) as described by Fang et al. [21].
Statistical analysis
Data in this study were expressed as mean ± SEM from at
least three separate experiments. Unless otherwise noted,
the differences between groups were analyzed using Stu-
dent’s t-test (two groups) or ANOVA (≥ three groups). All
statistical analyses were performed using SPSS 13.0 soft-
ware (Chicago, IL, USA). All tests employed were two-
sided, and p <0.05 was set to be considered statistically
significant.
Results
DKK1 is overexpressed in human hepatocellular
carcinoma cell lines
To determine the possible role of DKK1 in human HCC,
the levels of DKK1 mRNA in four different hepatocellular
carcinoma cell lines were compared with that in the nor-
mal liver cell line by using RT-PCR. We observed that the
mRNA expression of DKK1 in Huh7, SMMC7721, and
Bel7402 cell lines were much higher in comparison with
that in control normal QSG7701 hepatocytes (Figure 1A).
We further investigated the protein expression of DKK1
in these cells by western blotting. As shown in Figure 1B,
the higher protein level of DKK1 was confirmed in Huh7,
SMMC7721, and Bel7402 HCC cell lines, compared with









































Figure 1 DKK1 is overexpressed in HCC cells. A: The mRNA
expression of DKK1 in normal liver cell line (QSG7701) and HCC cell
lines (HepG2, SMMC7721, Huh7 and Bel7402). GAPDH was used as
an internal control. B: Western blot analysis of DKK1 in the same cell
lines as described in A. β-actin served as a loading control.
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both mRNA and protein level. In contrast, the level of
DKK1 mRNA and protein in HepG2 cells was comparable
to that in the normal liver cell line (QSG-7701). Therefore,
HepG2 and Bel7402 cells were selected for further study.
DKK1 overexpression did not influence the cell
proliferation rate and colony formation
Next, we asked for the functional role of DKK1 in
tumor cells. After stably transfected cells were individu-
ally selected, the DKK1 and the housekeeping gene
GAPDH mRNA levels were measured using RT-PCR.
Compared with the cells which without transfection or
transfected with Vector, the levels of DKK1 mRNA were
greatly up-regulated in HepG2 cells transfected with
DKK1 (Figure 2A). However, the tumor cells derived
from shDKK1-tranfectants showed a much lower level
of DKK1 mRNA in comparison with that derived from
shControl or nontransfected Bel7402 cells (Figure 2B).
Consistent with our RT-PCR data, Western blot analysis
also revealed that DKK1 protein levels were also obvi-
ously increased in HepG2 cells that transfected with
DKK1 (Figure 2C), while decreased in Bel7402 cells that
transfected with shDKK1, compared with their control
groups respectively (Figure 2D). The empty vector or
the control scrambled shRNA did not substantially
affect the endogenous DKK1 expression in both mRNA
and protein levels. Collectively, these findings indicated
that DKK1 can be stably overexpressed in HepG2 cells
and shDKK1 could effectively suppress the expression
of DKK1 in Bel7402 cells. Then we investigated whether
DKK1 regulates cell proliferation. When DKK1 was up-regulated in HepG2 cells, no change of proliferation
rates occurred compared with that without transfection
or transfected with Vector (Figure 2E). Next, we aimed
to investigate if loss of DKK1 may influence tumor cell
proliferation. Therefore, DKK1 was depleted using one
DKK1-specific shRNA and proliferation was assessed in
Bel7402 cells, which expressed high levels of DKK1 en-
dogenously. In these cells, remain no obvious change of
proliferation rates were observed (Figure 2F). Using
colony formation assay, although DKK1-transfectants
displayed a tendency of increased colonies (Figure 2G),
and shDKK1-transfectants showed a reduced tendency
(Figure 2H), however, the difference did not reach stat-
istical significance, compared with their control cells
respectively.
DKK1 promotes HCC cell migration and invasion
Given that DKK1 did not influence tumor cell proli-
feration or colony formation, then we investigated
whether DKK1 regulated HCC cell migration and inva-
sion, which are two of the most important features of
malignant cell behavior. First, we examined the role of
DKK1 in tumor cell migration by using wound scratch
assay. As illustrated in Figure 3A, enforced expression
of DKK1 significantly promoted wound closure com-
pared with that without transfection or transfected with
Vector in HepG2 cells, vice versa, down-regulation
of DKK1 remarkably attenuated the wound closure
(Figure 3D). To further identify these observations, we
examined the effects of DKK1 on HCC cell migration
using the Boyden chamber transwell without Martrigel.
Indeed, tumor cells derived from DKK1-transfectants
displayed a higher ability of migration, compared
with that derived from Vector or nontransfected cells
(Figure 3B). In contrast, tumor cells derived from
shDKK1-transfectants displayed a lower ability of mi-
gration (Figure 3E). Next, we determine the role of
DKK1 in tumor cell invasion. We performed these ex-
periments using transwell chamber with Matrigel. As
illustrated in Figure 3C, up-regulation of DKK1 expres-
sion significantly enhanced the number of HepG2 cells
that invaded through Matrigel in comparison with that
derived from Vector or nontransfected cells, however,
the number of Bel7402 cells that invaded through
Matrigel was sharply reduced after DKK1 was silenced
by a specific shRNA (Figure 3F). Consistently, in the
human HCC tissues, the primary tumors showed slightly
higher DKK1 expression, compared to those in the adja-
cent non-tumor liver tissues, moreover, the metastatic
tumors showed much higher DKK1 expression in com-
parison with that in the primary tumors (Figure 3G and
H). Collectively, these data demonstrate that DKK1 pro-
motes HCC cell migration and invasion in vitro and


























































Figure 2 DKK1 up-regulation or down-regulation did not influence HCC cell proliferation. The expression of DKK1 mRNA (A, B) and
protein (C, D) were detected in HepG2 cells without transfection (lane 1) or transfected with Vector (lane 2) or DKK1 (lane 3), or Bel7402 cells
without transfection (lane 1) or tumor cells transfected with shControl (lane 2) or shDKK1 (lane 3) using RT-PCR and western blotting. GAPDH and
β-actin were used as loading controls. E, F: MTT assay showed that up-regulation or down-regulation of DKK1 did not influence the proliferation
rates in HepG2 or Bel-7402 cells. G, H: enforced expression or suppression of DKK1 did not influence the colony formation in both HepG2 and
Bel7402 HCC cells. HepG2 cells without transfection or transfected with Vector or DKK1 (G), and Bel7402 cells that without transfection or
transfected with shControl or shDKK1 (H) were seed into 6-well plates and incubated in RPMI1640 supplemented with 10% FCS, the medium
was changed every three days. 15 days later, colonies were fixed and stained with 0.1% crystal violet in 20% methanol for 20 min. Colonies
composed of more than 50 cells were counted in each well. The data are represented as means ± SEM from 4 replicates in each of the 3
independent experiments.
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Then we investigate a potential mechanism for DKK1-
mediated HCC cell migration and invasion. It is well
known that DKK1 is a typical inhibitor of Wnt/β-catenin
signaling pathway, hence we examined that whetherDKK1 was able to inhibit the expression of β-catenin.
Firstly, we analyzed β-catenin expression using Immuno-
histochemical staining in 71 cases of human HCC tis-
sues. Of great interest, the DKK1 level was positively










































































Figure 3 DKK1 was involved in HCC cell migration and invasion. A: Wound healing assay indicated that DKK1 up-regulation promoted
HepG2 cell migration. B, C: Up-regulation of DKK1 significantly enhanced HepG2 cell migration and invasion. HepG2 cells without transfection or
transfected with Vector or DKK1 were added to the transwell chamber coated without or with Matrigel for 24 h. Representative images and the
number of migrated or invaded cells are shown. Analysis was performed in three separate experiments (n = 3). **, p <0.01. D: Wound healing
analysis of migration in Bel7402 cells. E, F: Depleting of DKK1 attenuated the migration and invasion in Bel7402 cells. Bel7402 cells without
transfection or transfected with shControl or shDKK1 cells were seeded into the transwell chamber coated without or with Matrigel and
incubated in RPMI1640 containing 10% FCS for 24 h. and then fixed and stained with crystal violet for 20 min. Representative images and the
number of migrated or invaded cells are shown. Results are presented as mean ± SEM (n = 3). **, p <0.01. G, H: Analysis of DKK1 expression in
primary (n = 30) and metastatic (n = 41) HCC tissues by IHC. Images were captured at × 200 for DKK1 staining. Scale bar = 50 μm. The data are
represented as means ± SEM. **, p <0.01.
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Figure 4 Upregulation of DKK1 promotes the expression of β-catenin. A: The representative images of IHC staining for β-catenin. Scale bar = 50
μm. B: β-catenin expression is positively correlated with DKK1 level in 71 human HCC tissues. The median of all 71 cases was chosen as the cutoff point
for separating low-DKK1 (n = 36) from high-DKK1 expressing tumors (n =35). C: DKK1 overexpression markedly enhanced the mRNA and protein level
of β-catenin in HepG2 cells. GAPDH and β-actin served as internal controls. D: up-regulation of DKK1 expression enhanced the cytoplasmic/nuclear
β-catenin accumulation in HepG2 tumor cells (original magnification, 100×). The expression level of β-catenin protein was detected with rabbit
polyclonal antibody and revealed by Cy3-conjugated secondary antibody (red). The nuclei were counterstained with Hoechst33342 (blue). E: Restoration
of DKK1 promoted the β-catenin-dependent transcriptional activity. Tumor cells were transfected with firefly luciferase reporter plasmids containing either
wild-type or mutant TCF binding sites (indicated as Wt or Mut on the X axis), and a Renilla luciferase expressing construct. The firefly luciferase activity of
each sample was normalized to the Renilla luciferase activity. The normalized luciferase activity of Vector-transfectants in each experiment was set as
relative luciferase activity. ** P < 0.01, compared with Vector-transfectants. F, G: Treatment with β-catenin inhibitor IWP-2 (1 μM) attenuated the
pro-migration and pro-invasion effect of DKK1. In (F), after scratching a wound and removing the floating cells, tumors cells without treatment (panel 1,
3) or incubated with 1 μM IWP-2 (panel 2, 4) were applied to the wound scratch assay for 24 h. In (G) tumors cells treated as in (F) were applied to
transwell chamber coated with Matrigel and then incubated for 24 h. The data are represented as means ± SEM. *, p <0.05; **, p <0.01.
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β-catenin expression, but remarkably increased the mRNA
and protein level of β-catenin in HepG2 cells, compared
with those of control cells (Figure 4C). In addition, by
using immunofluorescence staining, we also observed that
up-regulation of DKK1 expression noticeably promoted
the cytoplasmic/nuclear β-catenin accumulation in HepG2
cells (Figure 4D). Furthermore, dual-luciferase reporter
analysis also showed that restoration of DKK1 significantly
promoted the activity of firefly luciferase that carried
wildtype but not mutant TCF binding sites (Figure 4E).
In contrast, the blockage of DKK1 dramatically attenu-
ated the mRNA and protein level of β-catenin in
Bel7402 cells (Figure 5A). Moreover, the activity of fire-
fly luciferase that carried wildtype but not mutant TCF
binding sites was dramatically attenuated when DKK1
was silenced in Bel7402 cells (Figure 5B). These findings
indicated that β-catenin may be an important target
downstream of DKK1.
DKK1 exert its function by promoting β-catenin signaling
The role of β-catenin in DKK1-mediated phenotypes
was then evaluated. First, we examined whether block-
age of β-catenin could attenuated the effect of DKK1
expression. As expected, upon treatment with β-catenin
inhibitor IWP-2, the promotive effect of DKK1 on mi-
gration and invasion was significantly attenuated in
DKK1-transfectants, whereas there were no statistically
significant differences in those of Vector-transfectants
(Figure 4F and G). On the other hand, overexpression of
β-catenin in shDKK1-transfectants restored the tran-
scription of β-catenin (Figure 5C), and attenuated the
inhibitory effect of shDKK1 on invasion (Figure 5D). As
GSK3β is an important upstream target of β-catenin sig-
naling, we further analyzed whether blockage of GSK3β
could mimic the effect of β-catenin expression. Upon
treatment with GSK3β inhibitor LiCl, the inhibitory ef-
fect of shDKK1 on migration (Figure 5E) and invasion
(Figure 5F) was dramatically released.
It is well known that DKK1 antagonizes Wnt signaling
by direct high-affinity binding to the extracellular domain
of Wnt coreceptor lipoprotein receptor-related protein 6
(LRP6) and inhibiting the internalization of LRP6, which
is responsible for the inhibition of GSK3β and activation
of Wnt signaling cascade downstream. Therefore, two
pairs of primers were selected to examine the mRNA ex-
pression of LRP6: one for the extracellular domain of
LRP6, responsible for DKK1 binding, and another for the
intracellular region, essential for inhibiting GSK3β [22]. Of
great note, neither the extracellular domain nor the intra-
cellular domain of LRP6 were changed, although the ex-
pression of β-catenin was dramatically altered upon DKK1
up-regulation (Figure 6A) or knockdown (Figure 6B). In
addition, western blotting analysis also displayed that theprotein level of LRP6 and GSK3β was not changed in
comparison with those of control groups (Figure 6C and
D). Whereas restoration of DKK1 significantly enhanced
the expression of β-catenin, and the protein level of its
downstream target c-Myc was also increased in HepG2
cells (Figure 6C). Vice versa, the blockage of DKK1 re-
duced the expression of β-catenin and c-Myc in Bel7402
cells (Figure 6D). Furthermore, upon β-catenin inhibitor
IWP-2 treatment, the expression of β-catenin was attenu-
ated (Figure 6E), which is consistent with the above obser-
vation on migration (Figure 4F) and invasion (Figure 4G),
compared with the control. On the other hand, GSK3β in-
hibitor LiCl indeed recovered the expression of β-catenin
in shDKK1-transfectants (Figure 6F), in agreement with the
results of Figure 5E and F. These findings indicated that
DKK1 may positively regulate the expression of β-catenin
through a non-canonical Wnt signaling pathway.
MMP7 is an important target downstream of DKK1/β-
catenin signaling pathway
Considering that MMP7 is one of the most important tar-
get genes downstream of β-catenin/TCF signaling, in
addition, MMP7 has been shown to play a crucial role in
promoting tumor cell migration and invasion [23]. We
then investigate whether DKK1 regulated the expression
of MMP7. As shown in Figure 7A and B, introduction of
DKK1 significantly enhanced the mRNA and protein level
of MMP7 in HepG2 cells (Figure 7A). Vice versa, when
DKK1 was silenced by shRNA, the expression of MMP7
mRNA and protein were remarkably down-regulated in
Bel7402 cells (Figure 7B). Moreover, upon treatment with
β-catenin inhibitor IWP-2, the protein level of MMP7 was
reduced in a dose-dependent manner (Figure 7C). Then
we examined whether introduction of MMP7 could mimic
the effect of β-catenin expression. As expected, HepG2
cells transiently transfected with MMP7 plasmids dis-
played a much invasive activity (Figure 7D and E), which
phenocopied those of enhanced β-catenin expression.
Taken together, our findings suggested that DKK1 pro-
motes HCC cell migration and invasion at least partly by
promoting β-catenin/MMP7 signaling.
Discussion
In this work, we found that DKK1 is strongly overex-
pressed in both HCC cell lines and clinical HCC sam-
ples. The expression of DKK1 is positively associated
with the migration and invasion, but did not influence
the proliferation or colony formation of HCC. Mechan-
istically, we demonstrated that DKK1 promoted HCC
cell migration and invasion by upregulating β-catenin/
MMP7 pathway. During this manuscript in preparation,
Tao et al. showed that increased DKK1 expression could
promote HCC invasion and metastasis via up-regulation



































- + - + LiCl
shControl shDKK1
- + - + LiCl
Wt Mut
- -+ + LiCl






Figure 5 Beta-catenin is involved in the dual promotive function of DKK1 on tumor migration and invasion. A: Knockdown of DKK1
repressed the mRNA and protein level of β-catenin in Bel7402 cells. B: Silencing of DKK1 attenuated the β-catenin-dependent transcriptional
activity. Tumor cells were transfected with firefly luciferase reporter plasmids containing either wild-type or mutant TCF binding sites (indicated as
Wt or Mut on the X axis), and a Renilla luciferase expressing construct. The firefly luciferase activity of each sample was normalized to the Renilla
luciferase activity. The normalized luciferase activity of shControl-transfectants in each experiment was set as relative luciferase activity 1.
Therefore, no error bar is shown for shControl-transfectants. **, p < 0.01, compared with shControl-transfectants. C: Transient expression of
β-catenin in Bel7402-shDKK1 cells was detected by RT-PCR analysis. Bel7402-shDKK1 cells transfected with pcDNA3 (lane 2) or pcDNA3-β-catenin
(lane 3) were analyzed using RT-PCR. D: Restoration of β-catenin reversed the anti-invasion effect of shDKK1. E, F: Treatment with GSK3β inhibitor
LiCl (5 mM) attenuated the anti-migration and anti-invasion effect of shDKK1. In (E), after scratching a wound and removing the floating cells,
tumors cells without treatment (panel 1, 3) or incubated with 5 mM LiCl (panel 2, 4) were applied to the wound scratch assay for 24 h. In (F)
tumors cells treated as in (E) were applied to transwell chamber coated with Matrigel and then incubated for 24 h. The data are represented
as means ± SEM. *, p <0.05; **, p <0.01.
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Figure 6 DKK1 regulates β-catenin expression through the non-canonical Wnt pathway. A: Restoration of DKK1 promoted the mRNA
expression of β-catenin in HepG2 cells. B: Knockdown of DKK1 attenuated β-catenin mRNA expression in Bel7402 cells. C: Restoration of DKK1
promoted the protein levels of β-catenin and c-Myc in HepG2 cells. D: Knockdown of DKK1 attenuated the protein levels of β-catenin and c-Myc
in Bel7402 cells. E: IWP-2 attenuated the positive effect of DKK1 on β-catenin expression in HepG2 cells. F: Treatment with GSK3β inhibitor LiCl
restored the expression of β-catenin in Bel7402 cells.
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http://www.molecular-cancer.com/content/12/1/157pathway [15]. Their results in combination with our
findings in this study, revealed the significant role of
DKK1 in HCC cell migration and invasion.
Recently, Shen et al. demonstrated that DKK1 as a
serum biomarker can improve the diagnostic accuracy for
HCC in a large-scale, multicenter study. Their study re-
vealed that the levels of DKK1 in serum are significantly
higher in patients with HCC than in all controls [16]. In
the present data, we found that DKK1 is expressed at high
levels in 3 of 4 HCC cell lines in comparison with that of
the control normal liver cell line. Furthermore, specific
DKK1 was predominantly observed to be expressed in
HCC tissues but not in the adjacent non-tumor liver tis-
sues. All these findings indicated that DKK1 performs as
an oncogenic factor rather than a tumor-suppressor in
HCC.
Interestingly, in this study, we did not find that DKK1
expression influence HCC cell proliferation and colony
formation, which are two of the most important features
among the malignant cell behavior. While Qin et al.
found that overexpression of DKK1 by transfection wasable to inhibit the growth and migration in M-H7402
cells [14]. One possible explanation is that the impact of
DKK1 on cell proliferation may vary in different cell
types. Because the tumor cells they used is a metastatic
subclone of human HCC H7402 cells by isolating from
transplantation of H7402 cells into severe combined im-
munodeficient (SCID) mice [14]. In contrast, our experi-
ments were performed by using two HCC cell lines,
namely HepG2 and Bel7402.
Besides cell proliferation, migration and invasive cap-
acity of cells are also two of the most important features
of malignant cell behavior. Intriguingly, up-regulation of
DKK1 significantly promoted HCC cell migration and in-
vasion, vice versa, when DKK1 is repressed by a DKK1-
specific shRNA, the tumor cell migration and invasion is
markedly reduced. More importantly, in HCC tissues, the
metastatic tumors showed much higher DKK1 expression
comparison with that in the primary tumors. Consistent
with our present data, Tung et al. found that knockdown
of DKK1 significantly reduced both migratory and invasive
















































Figure 7 DKK1 regulates the expression of MMP7. A: Ectopic expression of DKK1 increased the mRNA and protein expression of MMP7 in
HepG2 cells. HepG2 cells without transfection (lane 1) or transfected with Vector (lane 2) or DKK1 (lane 3) were analyzed using RT-PCR and
western blotting. B: Knockdown of DKK1 suppressed the MMP7 mRNA and protein level in Bel7402 cells. RT-PCR and western blotting analysis
were respectively used to detect the RNA and protein level of MMP7 in Bel7402 cells without transfection or cell transfected with shControl or
shDKK1. GAPDH and β-Actin were used as internal controls. C: β-catenin inhibitor inhibited the expression of MMP7 in Bel7402 cells. Bel7402 cells
were treated without or with various concentration of β-catenin inhibitor (IWP-2) for 24 h, and then the whole cell lysates were analyzed by
western blotting for MMP7 expression, β-actin served as internal control. D: Transient expression of MMP7 in HepG2 cells detected by RT-PCR
analysis. HepG2 cells without transfection (lane 1) or transfected with Vector (lane 2) or DKK1 (lane 3) were analyzed using RT-PCR. E: Upregulation
of MMP7 mimicked the pro-invasion effect of DKK1 overexpression. HepG2 cells transfected with empty vector (pCMV6-XL5) or pCMV6-XL5-MMP7
were applied to transwell chamber coated with Matrigel. The data are represented as mean ± SEM. **, p <0.01.
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reported that DKK1 could promote HCC invasion and
metastasis in vitro and in vivo [15]. Moreover, the in-
creased expression of DKK1 closely correlates with mul-
tiple tumor nodes, high Edmondson-Steiner grade and
vein invasion, as well as poor overall and disease-free sur-
vival of HCC [15]. Taken together, our results in combined
with the findings from others, suggesting that DKK1 plays
an important role in promoting HCC cell migration and
invasion.
Deregulation of Wnt/β-catenin signaling pathway is a
hallmark of major gastrointestinal cancers including HCC[24]. It is well-known that β-catenin is the chief effector
downstream of this pathway. Approximately one third of
HCCs have been reported to be associated with the aber-
rant expression of β-catenin [25]. β-catenin plays a pivotal
role in regulating the HCC development and tumorigen-
esis through its association with E-cadherin in cell-cell ad-
hesion, interaction with the hepatocyte growth factor
(HGF) receptor c-Met and regulation the canonical Wnt/
β-catenin signaling pathway [26]. DKK1 acts as a typical
inhibitor of canonical Wnt/β-catenin pathway. Interest-
ingly, several years ago, Yu et al. reported that the mRNA
and protein expression levels of DKK1 are predominantly
Chen et al. Molecular Cancer 2013, 12:157 Page 13 of 14
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sion is positively correlated with the total β-catenin accu-
mulation in both HCC cell lines and clinical samples [27].
Along the same line of argument, Xu et al. recently re-
ported that up-regulation of DKK1 in their study signifi-
cantly correlates with the cytoplasmic/nuclear β-catenin
accumulation in triple negative breast cancers [24]. Here,
our data clearly suggested that DKK1 can directly promote
tumor cell migration and invasion by stimulating β-catenin
transcription and translation through a non-canonical Wnt
signaling pathway in HCC cells. This conclusion is based
on the following evidence. Firstly, DKK1 restoration not
only markedly promotes both the level of β-catenin and
β-catenin-dependent transcriptional activity, but also pro-
motes the migration and invasion of HCC cells in vitro.
Moreover, a positive relationship of DKK1 expression with
β-catenin level was found in HCC tissues. Secondly, silen-
cing of DKK1 not only significantly suppresses β-catenin
expression and β-catenin-dependent transcriptional activ-
ity, but also attenuates the migration and invasion of HCC
cells. Thirdly, neither the mRNA level of LRP6 nor the
protein levels of LRP6 and GSK3β was affected by DKK1
expression.
MMP7, also known as matrilysin, is a secreted protein
implicated in a broad range of extracellular matrix sub-
strates destruction in various cancers. Additionally, MMP7
has been shown to play a crucial role for the invasive and
metastatic potential of tumor cells [28,29]. Recently, sev-
eral reports have shown that MMP7 is overexpressed in
both the cells and tissues of HCC [30,31]. Moreover, it is
well-known that MMP7 is one of the most important
downstream target genes of β-catenin/TCF-4 [32]. In some
tissues, β-catenin transcriptionally regulates MMP7. For
example, β-catenin activation induces the expression and
secretion of MMP7 and promotes the binding of T cell fac-
tor to the MMP7 promoter in kidney epithelial cells,
whereas delivery of the gene encoding DKK1 abolishes its
induction [32]. However, the relationship between MMP7
and DKK1 remain elusive in HCC. Here, we demonstrate
MMP7 is an important target downstream of DKK1 in
HCC cells, based on the following studies: overexpression
of DKK1 or upon GSK3β inhibitor treatment is associated
with enhanced level of MMP7, migration and invasion in
HCC cells, whereas knockdown of DKK1 by shRNA re-
presses MMP7 expression and inhibits migration and inva-
sion of HCC cells. In addition, β-catenin inhibitor IWP-2
suppresses the protein level of MMP7 in a dose dependent
manner and attenuates DKK1-mediated migration and in-
vasion of HCC cells. All these findings suggested that
DKK1 may enhance HCC cell migration and invasion by
promoting β-catenin/MMP7 signaling pathway.
Taken together, our findings demonstrated that DKK1
promote HCC cell migration and invasion at least partly
by promoting β-catenin/MMP7 signaling axis, whichsupports the notion that DKK1 could serve as a diagnos-
tic biomarker for monitoring HCC development and
progression. In addition, as DKK1 down-regulation can
reduce the migration and invasion of HCC cells, it is a
potential therapeutic strategy for advanced HCC.Additional file
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